FLGT
Fulgent Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$18.52
−5.88%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$19.59
From 52W high−39.96%
Volume145907.00
Market cap$509.67M
P/E (TTM)—
P/S (TTM)1.6x
Div yield—
Key dataNov 5, 2026
Open
$19.59
From 52W high
−39.96%
Volume
145907.00
Market cap
$509.67M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
40.3
MomentumView details →
1D Return
−5.88%
YTD Return
−26.57%
SummaryUpdated Jun 1, 2026
Fulgent Genetics, Inc. (NASDAQ:FLGT) is a California-based medical diagnostics and genetic testing company founded in 2011 and headquartered in Temple City, California. The company went public in September 2016 and has evolved from a COVID-19 testing provider during the pandemic to a comprehensive genetic testing and precision medicine company. Today, Fulgent operates three main business segments: precision diagnostics, anatomic pathology, and biopharma services, while also developing therapeutic drugs through its Fulgent Pharma division.
Similar companies
Latest newsMore news →
Fulgent Genetics announced that management will host an investment-community conference call to discuss the third-quarter 2026 results.21d agoFulgent Genetics announced that it will release its third-quarter 2026 financial results after the market closes on November 5, 2026.21d agoFulgent Genetics, Inc. reported a quarterly loss of $0.58 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.46 per share, compared to earnings of $0.07 per share a year ago.98d ago